Lassman Law+Policy provides comprehensive support on FDA regulatory law to clients working on a variety of corporate transactions. Many large law firms with leading corporate practices do not have the type of specialized expertise in FDA regulatory law necessary to handle deals involving life sciences companies. Lassman Law+Policy works seamlessly with such firms to provide needed expertise on a range of corporate transactions, including Initial Public Offerings (IPOs), follow-on offerings, mergers, acquisitions, asset sales, and at-the-market (ATM) offerings.
Lassman Law+Policy not only conducts due diligence, when requested, but also drafts and reviews relevant sections of documents, such as S-1’s and merger agreements, and provides regulatory opinions. Lassman Law+Policy also assists life sciences companies in complying with SEC reporting requirements by reviewing 10-Ks and other disclosures.
Scott Lassman has extensive experience providing corporate support for life sciences transactions, having worked for years at and with some of the largest and most respected law firms in this space. Scott thus understands the fast-paced nature of many of these transactions and the need for close coordination with the deal team. He prides himself on being a consummate team player.
You are invited to contact Lassman Law+Policy for more information on the firm's counsel in transactions involving life sciences companies.